PLK1 and triple-negative breast carcinoma: In a triple negative breast cancer, the PLK1 inhibitor BI2536 impaired tumor growth also in vivo as single agent, but when combined with doxorubicin and cyclophosphamide this treatment gave a faster complete response and prevented relapses (163).